|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-5-20
|
|
pubmed:abstractText |
Technologies to increase tissue vascularity are critically important to the fields of tissue engineering and cardiovascular medicine. Currently, limited technologies exist to encourage angiogenesis and arteriogenesis in a controlled manner. In the present study, we describe an injectable controlled release system consisting of VEGF encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs). The majority of VEGF was released gradually over 2-4 days from the NPs as determined by an ELISA release kinetics experiment. An in vitro aortic ring bioassay was used to verify the bioactivity of VEGF-NPs compared with empty NPs and no treatment. A mouse femoral artery ischemia model was then used to measure revascularization in VEGF-NP-treated limbs compared with limbs treated with naked VEGF and saline. 129/Sv mice were anesthetized with isoflurane, and a region of the common femoral artery and vein was ligated and excised. Mice were then injected with VEGF-NPs, naked VEGF, or saline. After 4 days, three-dimensional microcomputed tomography angiography was used to quantify vessel growth and morphology. Mice that received VEGF-NP treatment showed a significant increase in total vessel volume and vessel connectivity compared with 5 microg VEGF, 2.5 microg VEGF, and saline treatment (all P < 0.001). When the yield of the fabrication process was taken into account, VEGF-NPs were over an order of magnitude more potent than naked VEGF in increasing blood vessel volume. Differences between the VEGF-NP group and all other groups were even greater when only small-sized vessels under 300 mum diameter were analyzed. In conclusion, sustained VEGF delivery via PLGA NPs shows promise for encouraging blood vessel growth in tissue engineering and cardiovascular medicine applications.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-10625391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-11055295,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-11777364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-11897410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-12099717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-12461084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-12549864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-12642354,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-15016633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-15147819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-16476119,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-18006856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-7509344,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-7525111,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-8334036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-9626071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20228260-9685870
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1522-1539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
298
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
H1959-65
|
|
pubmed:dateRevised |
2011-7-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20228260-Animals,
pubmed-meshheading:20228260-Aorta,
pubmed-meshheading:20228260-Biocompatible Materials,
pubmed-meshheading:20228260-Disease Models, Animal,
pubmed-meshheading:20228260-Dose-Response Relationship, Drug,
pubmed-meshheading:20228260-Drug Delivery Systems,
pubmed-meshheading:20228260-Femoral Artery,
pubmed-meshheading:20228260-Hindlimb,
pubmed-meshheading:20228260-Ischemia,
pubmed-meshheading:20228260-Lactic Acid,
pubmed-meshheading:20228260-Male,
pubmed-meshheading:20228260-Mice,
pubmed-meshheading:20228260-Mice, Inbred C57BL,
pubmed-meshheading:20228260-Nanoparticles,
pubmed-meshheading:20228260-Neovascularization, Physiologic,
pubmed-meshheading:20228260-Polyglycolic Acid,
pubmed-meshheading:20228260-Tomography, X-Ray Computed,
pubmed-meshheading:20228260-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth.
|
|
pubmed:affiliation |
Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr., Atlanta, GA 30332, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
